الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 168 |  |  |
| | | from | 168 | | |
Abstract
Diabetes mellitus is a well-known risk factor for poor clinical outcomes in people with Coronavirus Disease 2019 (COVID-19). However, it seems that these two illnesses are related in a reciprocal manner. The present COVID-19 epidemic had a significant influence on people with diabetes mellitus’ ability to maintain their blood glucose levels. The results can be divided into two categories: direct impacts (those associated with the viral infection directly) and indirect effects (those associated with the pandemic’s influence on blood glucose regulation or the application of recommended treatments specific to infections that also affect glucose homeostasis).
from December 2021 to December 2022, in the department of internal medicine at Minia University Hospital, conducted our study on the various alterations in hematological parameters and inflammatory markers in type 2 diabetic patients infected with COVID-19.
The results of the study showed that:
Demographic and anthropometric data of the studied groups were performed, The age was ranged in diabetics with COVID-19from (54-75) years with mean ± SD (65.3±6.8), diabetics without COVID-19 from (40-70) years with mean ± SD (55.3±8.6) and control group from(40-70) years with mean ± SD (47.6±6.4 )Females were more precipitated in this study 17 for diabetics with covid19, 16 for diabetics without COVID-19 and 21 for controls, There was no significant difference between the 3 groups as regards smoking. The duration of diabetes ranges from (14-32) yrs., with mean± SD (20.9±5.9) for diabetics with COVID-19, and from (4-19) yrs. With mean± SD (11.6±3.7) In diabetics without COVID-19.
In our study we had found that the diabetic with COVID-19 group showed poor glycemic control and significantly higher levels in FBG (p<0.001), 2hour Postprandial blood glucose (p<0.001), and HBA1c (p<0.001), than the diabetic and control groups, but the HOMA-IR and fasting insulin level was insignificant between diabetic with COVID-19 patients and diabetics. 20 of diabetics with COVID-19, and 15 0f diabetics without COVID-19 received insulin treatment.
The COVID-19 group of diabetics had considerably higher cholesterol and LDL levels than the diabetic group (p = 0.001 and 0.004 respectively), while the diabetics had significantly higher cholesterol and LDL levels than the controls (p = 0.001 and 0.001), respectively.
Compared to the diabetic and diabetic with COVID-19 groups, the control group’s HDL values are significantly higher (p = 0.001).
Conclusion
In conclusion, it has been demonstrated that poor glycemic control of diabetic patients had unfavorable outcomes on prognosis of COVID-19 and increases its related comorbidity and mortality. Poorly controlled COVID-19-positive diabetic individuals exhibit the most notable hematological profiles being anemia, thrombocytopenia, lymphocytopenia, and neutropenia. They also showed high RDW, MPV, and PDW, all of which are known to indicate severity in the COVID-19 prediction. The majority of them showed symptoms at presentation, including tachycardia and fever. They also had high infectivity and poorly controlled diabetes, which indicated a higher chance of severe COVID-19 manifestations, which are linked to worse outcomes and prognoses.
Fever, desaturation and tachypnea on admission, and higher white cell count, Procalcitonin, D-Dimer and CRP levels were associated with a reduced chance of discharge.